SHISEIDO IS NOT INTERESTED IN U.S. MASS MARKET
SHISEIDO IS NOT INTERESTED IN U.S. MASS MARKET, the firm declared in a March 27 letter to "The Pink Sheet." Commenting on a story in the March 26 issue of "The Pink Sheet," Shiseido Technical Liaison Representative Koji Yoshino asserted: "Shiseido is NOT looking for entry into the U.S. mass market. It is not our intention to diverge from our status as a prestigious cosmetic company." [EDITORS' NOTE: Emphasis was added by Yoshino.] The article in "The Pink Sheet" incorrectly combined recent indications of interest in U.S. OTC products by Shiseido with a blind ad in a trade assn. publication. Shiseido declares that the ad was not placed by the firm. The March 27 letter from Shiseido to "The Pink Sheet" states: "Neither Shiseido Cosmetics (America) Ltd. nor our parent company, Shiseido Co., Ltd., are responsible for the placement of a blind ad that appeared in the Proprietary Assn. Executive Newsletter. It was erroneous for you to conjecture that it was this company, and, based on that presumption, to build an entire scenario on that premise." The ad cited a "Japanese pharmaceutical company" which was interested in "novel, fast-moving products." "The Pink Sheet" article further identified Koji Yoshino as the "point man" in the licensing search. Yoshino described his responsibilities in his letter as "solely to conduct research and development of cosmetic products produced by Shiseido and for Shiseido products only." He added that he "has not the responsibility, nor has he the authority for such a licensing search on behalf" of the Shiseido home office.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth